# US 2010/0061932 A1 · Peptides useful as cell-penetrating peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0061932 A1
- Document ID: US20100061932A1
- Status: Published application
- Kind: A1
- Application number: 12/159,226
- Filed: 2006-10-25
- Published: 2010-03-11
- Earliest claimed: 2005-12-30
- Assignees: Evonik Roehm GmbH
- Inventors: Roland Brock; Rainer Fischer; Mariola Fotin-Mleczek; Hansjoerg Hufnagel; Norbert Windhab
- Web page: https://patentgrep.com/patent/US20100061932A1

## CPC

- C07K 14/47: from mammals
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/644: {Transferrin, e.g. a lactoferrin or ovotransferrin}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 2039/53: {DNA (RNA) vaccination}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to a peptide having an amino acid sequence comprising at least 8 consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein, whereby the peptide is suitable to act as a cell-penetrating peptide.

## Claims

### Claim 1

A peptide having an amino acid sequence comprising at least 8 consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein, whereby the peptide is suitable to act as a cell-penetrating peptide.

### Claim 2 (depends on 1)

The peptide according to claim 1, whereby the peptide comprises at least four cationic amino acids.

### Claim 3 (depends on 1)

The peptide according to claim 1, whereby the human lactoferrin protein has an amino acid sequence according to SEQ. ID. No. 1 and the bovine lactoferrin protein has an amino acid sequence according to SEQ. ID. No. 2.

### Claim 4 (depends on 1)

The peptide according to claim 1, whereby the peptide comprises at least two Cys residues or analogs thereof.

### Claim 5 (depends on 4)

The peptide according to claim 4, whereby the peptide comprises a disulfide bond created by two Cys residues or an analogous bond formed by the cysteine analogs.

### Claim 6 (depends on 1)

The peptide according to claim 1, whereby the peptide comprises a moiety having an alpha-helical conformation of about 12 to 20 amino acids in length, and a moiety having a beta-sheet conformation of about 8 to 12 amino acids in length.

### Claim 7 (depends on 1)

The peptide according to claim 1, whereby the peptide comprises from about 8 to about 60 amino acid residues.

### Claim 8 (depends on 7)

The peptide according to claim 7, whereby the peptide comprises from about 20 to about 45 amino acid residues.

### Claim 9 (depends on 1)

The peptide according to claim 1, whereby the peptide has an amino acid sequence corresponding to amino acid positions 20 to 64 of the amino acid sequence according to SEQ. ID. No.1.

### Claim 10 (depends on 1)

The peptide according to claim 1, whereby the peptide has an amino acid sequence, whereby the N-terminal end of the peptide is an amino acid corresponding to amino acid positions 20 to 64 of the amino acid sequence according to SEQ. ID. No.1 or SEQ. ID. No. 2.

### Claim 11 (depends on 1)

The peptide according to claim 1, whereby the peptide is selected from the group comprising
a peptide having the amino acid sequence KCFQWQRNMRKVRGPPVSCIKR (SEQ. ID. No.3),
a peptide having the amino acid sequence CFQWQRNMRKVRGPPVSC (SEQ. ID. No.4),
a peptide having the amino acid sequence FQWQRNMRKVRGPPVS (SEQ. ID. No.5),
a peptide having the amino acid sequence FQWQRNMRKVR (SEQ. ID. No.6),
a peptide having the amino acid sequence KCRRWQWRMKKLGAPSITCVRR (SEQ. ID No. 29), and
a peptide having the amino acid sequence CRRWQWRMKKLGAPSITC (SEQ. ID No. 30),
and derivatives thereof.

### Claim 12 (depends on 11)

The peptide according to claim 11, whereby the peptide comprise a sequence according to SEQ. ID No. 3, SEQ. ID No. 4, SEQ. ID No. 29, SEQ. ID No. 30 or a derivative of said sequences with an sequence identity of at least 40%.

### Claim 13 (depends on 11)

The peptide according to claim 11, whereby the peptide is a derivative of the peptides according to any of SEQ. ID. No. 2 to 5, whereby the methionine residues is replaced by an amino acid selected from the group comprising valine, isoleucine, norvaline, leucine and norleucine.

### Claim 14 (depends on 13)

The peptide according to claim 13, whereby the peptide is a peptide having an amino acid sequence selected from the group comprising
(SEQ. ID. No. 7)
KCFQWQRNVRKVRGPPVSCIKR
(SEQ. ID. No. 8)
KCFQWQRNIRKVRGPPVSCIKR
(SEQ. ID. No. 9)
KCFQWQRNXRKVRGPPVSCIKR, whereby X is norvaline,
(SEQ. ID. No. 10)
KCFQWQRNLRKVRGPPVSCIKR,
(SEQ. ID. No. 28)
KCFQWQRNXRKVRGPPVSCIKR, whereby X is norleucine,
(SEQ. ID. No. 11)
CFQWQRNVRKVRGPPVSC,
(SEQ. ID. No. 12)
CFQWQRNIRKVRGPPVSC,
(SEQ. ID. No. 13)
CFQWQRNXRKVRGPPVSC, whereby X is norvaline,
(SEQ. ID. No. 14)
CFQWQRNLRKVRGPPVSC,
(SEQ. ID. No. 15)
CFQWQRNXRKVRGPPVSC, whereby X is norleucine,
(SEQ. ID. No. 16)
FQWQRNVRKVRGPPVS,
(SEQ. ID. No. 17)
FQWQRNIRKVRGPPVS,
(SEQ. ID. No. 18)
FQWQRNXRKVRGPPVS, whereby X is norvaline,
(SEQ. ID. No. 19)
FQWQRNLRKVRGPPVS,
(SEQ. ID. No. 20)
FQWQRNXRKVRGPPVS, whereby X is norleucine,
(SEQ. ID. No. 21)
FQWQRNVRKVR,
(SEQ. ID. No. 22)
FQWQRNIRKVR,
(SEQ. ID. No. 23)
FQWQRNXRKVR, whereby X is norvaline,
(SEQ. ID. No. 24)
FQWQRNLRKVR,
and
(SEQ. ID. No. 25)
FQWQRNXRKVR, whereby X is norleucine.

### Claim 15 (depends on 11)

The peptide according to claim 11, whereby the derivatives have a linkage group selected from the group comprising thioethers, whereby the linkage group replaces the disulfide bond formed by these Cys residues.

### Claim 16 (depends on 1)

The peptide according to claim 1, whereby the peptide is radioactively labelled, preferably by having incorporated a radioactively labelled amino acid, whereby the radioactively labelled amino acid is a tritium-labelled amino acid.

### Claim 17 (depends on 1)

The peptide according to claim 1, whereby the peptide further comprises a moiety which is suitable for detection using a method for detection, whereby such moiety is selected from the group comprising fluorophores, radioactive tracers and haptens, whereby preferably the hapten is biotin.

### Claim 18 (depends on 1)

A complex comprising a peptide selected from the group comprising a peptide according to claim 1, human lactoferrin and bovine lactoferrin, and a cargo molecule.

### Claim 19 (depends on 18)

The complex according to claim 18, whereby the cargo molecule is covalently or non-covalently bound to the peptide.

### Claim 20 (depends on 18)

The complex according to claim 18, whereby the cargo molecule is selected from the group comprising nucleic acids, amino acids, peptides, proteins, carbohydrates, lipids, and small molecules and mixtures of any of thereof.

### Claim 21 (depends on 18)

The complex according to claim 18, whereby the cargo molecule is present as or part or a structure, whereby the structure is selected from the group comprising nanoparticles, microparticles, liposomes and micelles.

### Claim 22 (depends on 20)

The complex according to claim 20, whereby the nucleic acid is a nucleic acid selected from the group comprising DNA molecules, RNA molecules, PNA molecules, siRNA molecules, antisense molecules, ribozymes, aptamers, spiegelmers and decoy molecules.

### Claim 23 (depends on 20)

The complex according to claim 20, whereby the peptide is selected from the group comprising peptides for vaccination.

### Claim 24 (depends on 20)

The complex according to claim 20, whereby the nucleic acid is a nucleic acid-based vaccine.

### Claim 25 (depends on 20)

The complex according to claim 20, whereby the nano-particles and/or the micro-particles comprise or consist of a pharmaceutically active compound.

### Claim 26 (depends on 1)

A composition comprising at least a peptide selected from the group comprising a peptide according to claim 1, human lactoferrin and bovine lactoferrin, and a cargo molecule.

### Claim 27 (depends on 18)

A composition comprising a complex according to claim 18.

### Claim 28 (depends on 1)

A nucleic acid coding for a peptide according to claim 1, preferably having a nucleic acid sequence according to SEQ. ID. No. 26 or SEQ. ID. No. 27.

### Claim 29 (depends on 28)

A composition comprising a nucleic acid according to claim 28 and a cargo molecule.

### Claim 30 (depends on 29)

The composition according to claim 29, whereby the cargo molecule is a nucleic acid and more particularly a RNA suitable for vaccination.

### Claim 31 (depends on 29)

The composition according to claim 29, whereby the cargo molecule is a nucleic acid coding for a peptide.

### Claim 32 (depends on 28, 31)

The composition according to claim 31, whereby the nucleic acid according to claim 28 is operably linked to the nucleic acid coding for a peptide.

### Claim 33 (depends on 28, 31)

The composition according to claim 31, whereby the nucleic acid according to claim 28 and the nucleic acid coding for a peptide are linked in-frame.

### Claim 34 (depends on 31)

The composition according to claim 31, whereby the peptide is a pharmaceutically active agent.

### Claim 35 (depends on 1)

Use of a peptide according to claim 1 as a cell-penetrating peptide.

### Claim 36

The method of using human lactoferrin or a functional derivative thereof or of bovine lactoferrin or a functional derivative thereof as a cell-penetrating peptide.

### Claim 37 (depends on 36)

The method according to claim 36, whereby the human lactoferrin has an amino acid sequence comprising amino acid positions 20 to 711 of the amino acid sequence according to SEQ. ID. No. 1 or functional derivative thereof and/or the bovine lactoferrin has an amino acid sequence comprising amino acid positions 20 to 708 of the amino acid sequence according to SEQ. ID. No. 2 or a functional derivative thereof.

### Claim 38 (depends on 1)

The method of using a peptide according to claim 1 as a transfection agent.

### Claim 39

The method of using a human lactoferrin or a functional derivative thereof or of bovine lactoferrin or a functional derivative thereof as a transfection agent.

### Claim 40 (depends on 39)

The method according to claim 39, whereby the human lactoferrin has an amino acid sequence comprising amino acid positions 20 to 711 of the amino acid sequence according to SEQ. ID. No. 1 and/or the bovine lactoferrin has an amino acid sequence comprising amino acid positions 20 to 708 of the amino acid sequence according to SEQ. ID. No. 2 or a functional derivative thereof.

### Claim 41 (depends on 26)

The method of using a composition according to claim 26 for the manufacture of a medicament.

### Claim 42 (depends on 41)

The method according to claim 41, whereby the cargo molecule is a pharmaceutically active agent.

### Claim 43 (depends on 26)

The method of using a composition according to claim 26 for the manufacture of a diagnostic agent.

### Claim 44 (depends on 43)

The method according to claim 43, whereby the cargo molecule is a diagnostic marker.
